Zydus completes USD 166.33 mn acquisition of US-listed Assertio Holdings

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

ZYDUSLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.6%Reaction day

₹1079.80

prior close

₹1069.90

announcement price

After-mkt

timing

Nifty 100market+0.4%-2.0% vs market

Pharmaceuticals peers, median of 162sector-0.1%-1.4% vs sector

On the reaction day the stock moved 2.0 pts less than Nifty 100 and 1.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.4

10m

+0.1

15m

+0.1

30m

+0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.6+0.4-2.0-0.1-1.4

Next day

-0.5+0.8-1.4+0.3-0.8

-0.7+0.2-0.9+0.6-1.3

+0.5+0.7-0.2+1.0-0.5

+3.0-0.5+3.5+1.7+1.3

+1.6+0.2+1.4+1.6-0.1

+4.1-0.2+4.4+1.7+2.4

15d

+7.5-0.2+7.7+3.6+4.0

+5.9+1.2+4.7+3.1+2.8

+4.8+1.7+3.1+4.2+0.6

+5.2-2.6+7.8+8.6-3.4

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Zydus Lifesciences has completed the acquisition of Assertio Holdings Inc. (formerly Nasdaq: ASRT), a US specialty oncology pharma company, making it a wholly owned subsidiary. Deal priced at USD 23.50 per share in cash, totalling USD 166.33 million on a fully diluted basis. Assertio's key product ROLVEDON®, a USFDA-approved biologic for chemotherapy support, had CY2025 revenue of USD 68.23 million.

Likely market impact

Expands Zydus's US specialty oncology presence with an approved biologic and commercial infrastructure. All-cash deal, no equity dilution or related-party concerns.